# Yidu Tech's Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines

- Link: https://www.thailand-business-news.com/pr-news/yidu-techs-gong-yingying-at-summer-davos-building-evidence-infrastructure-to-expand-access-to-innovative-medicines
- Published: 2026-06-24T16:30:00+07:00
- Author: PR Newswire

DALIAN, China, June 24, 2026 /PRNewswire/ — On June 23, at the 17th Annual Meeting
of the New Champions (Summer Davos 2026) hosted by the World Economic Forum in Dalian,
Gong Yingying, Founder and Chairlady of Yidu Tech, participated in the panel discussion"
Faster Drugs, Better Access?". She shared her perspectives on the structural transformation
of global pharmaceutical R&D and how AI and healthcare data infrastructure are reshaping
drug development and clinical practice.

The session was moderated by Li Xin, Managing Editor of Caixin Global, and featured
fellow panelists Giovanni Caforio, Chair of the Board of Novartis, Ren Minghui, 
Professor at the School of Public Health of Peking University, and Eric Tse S Y,
Chief Executive Officer of SBP Group.

**From Data to Evidence: The Core Infrastructure Behind Medical AI**

China is now the world’s second-largest hub for innovative drug development, with
clinical trial activity continuing to expand rapidly. Yet challenges such as fragmented
data, lengthy development timelines, patient recruitment difficulties, and inefficient
evidence generation continue to limit the accessibility of innovative therapies.

According to Gong, these challenges are not merely issues of process efficiency;
they stem from a deeper fragmentation of healthcare data. "Data is scattered, inconsistent,
and disconnected," she noted, describing this as one of the biggest barriers preventing
AI from delivering its full value in healthcare.

This challenge is precisely why Yidu Tech chose to invest in healthcare data infrastructure
from the ground up.

Gong outlined a four-layer architecture for medical AI: the computing layer, foundation
models, healthcare-foundational models, and, most importantly, a high-quality data
pool. In essence, this data pool serves as an "evidence layer." Raw data alone cannot
support clinical decision-making. Only after continuous standardization, governance,
and transformation into traceable, verifiable, and structured information can data
evolve into a trustworthy clinical evidence system.

Built upon this standardized evidence foundation, healthcare organizations can develop
responsible, controllable, and safety-compliant AI agents. This integrated infrastructure,
Gong emphasized, has become a critical enabler of more efficient and higher-quality
drug development.

The practical embodiment of this vision is Yidu Tech’s proprietary "AI Medical Brain,"
YiduCore. By transforming fragmented healthcare data into structured disease knowledge
and research capabilities, YiduCore supports a wide range of healthcare applications.
As of September 30, 2025, YiduCore had cumulatively processed and analyzed nearly
7 billion authorized medical records, connected more than 10,000 healthcare institutions,
and built a disease knowledge graph covering virtually all known diseases.

**Data Infrastructure Is Directly Improving Drug Development Efficiency**

Leveraging its extensive network of leading hospitals and clinical research partners
across China, Yidu Tech has extended its healthcare data infrastructure beyond hospitals
to support the entire clinical research and drug development value chain, creating
systematic applications across real-world studies and clinical trials.

At the early stage of drug development, Yidu Tech’s disease knowledge graph helps
researchers identify promising research directions, design clinical trial protocols,
and conduct feasibility assessments. This reduces the risks associated with poorly
designed studies, implementation challenges, and resource inefficiencies, lowering
the cost of trial-and-error in R&D.

During trial execution, the platform enables intelligent patient identification 
and matching across regions and research centers, significantly improving recruitment
efficiency and shortening enrollment timelines. It addresses long-standing challenges
such as slow recruitment, low matching accuracy, and insufficient patient diversity.

At the same time, AI-powered quality control, real-time data validation, and intelligent
monitoring and early warning of adverse events support dynamic oversight throughout
the clinical trial lifecycle. These capabilities improve data quality and compliance
while reducing operational risks.

In the post-development phase, the platform’s standardized evidence layer enables
efficient real-world data curation, evidence generation, and patient cohort analysis.
These capabilities support post-marketing studies, indication expansion, reimbursement
decisions, and evidence-based clinical adoption, helping create a complete value
cycle from innovative drug development to broader patient access.

Gong noted that while clinical trial optimization historically relied heavily on
human expertise, standardized data infrastructure combined with AI has now become
a prerequisite for conducting high-quality clinical research and accelerating innovative
drug development. What was once viewed as a value-added enhancement has become an
essential component of industry innovation.

**Taking Medical AI Global: Data Sovereignty and Deep Localization**

Addressing global collaboration and data governance, Gong emphasized that healthcare
data must always be managed with security and compliance as top priorities.

Under regulatory frameworks around the world, healthcare data is typically stored
within sovereign government-controlled cloud environments. Independent third parties
are responsible for ensuring data security, managing access permissions, auditing
data usage, and enforcing compliance requirements.

She stressed that healthcare is fundamentally different from industries that can
deploy standardized global products. Healthcare delivery is deeply shaped by local
regulations, policies, and public health needs, making localization essential for
any international expansion strategy.

As an example, Gong highlighted Yidu Tech’s collaboration in Brunei. Through a jointly
operated venture with the government and a shared technical team, Yidu Tech co-manages
BruHealth, Brunei’s national digital health platform. While fully respecting local
data sovereignty and privacy requirements, the partnership brings proven AI healthcare
capabilities to support digital health services tailored to the needs of local residents.

Gong concluded that Yidu Tech’s long-term investment in healthcare AI infrastructure
is driven by a simple objective: ensuring that healthcare innovation translates 
into tangible benefits for patients. Technology is only a tool; the ultimate goal
is to make healthcare systems more efficient, trustworthy, and accessible.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Yidu Tech's Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines ](http://www.prnasia.com/story/archive/4991164_CN91164_0?rand=184833)
